Tarsus (TARS) director William Link receives 2,954 shares from RSU vesting

Rhea-AI Filing Summary

LINK WILLIAM J PHD reported acquisition or exercise transactions in this Form 4 filing.

Tarsus Pharmaceuticals, Inc. director William J. Link, PhD received 2,954 shares of common stock through the settlement of an equal number of vested Restricted Stock Units. These RSUs were granted on June 12, 2025 for his service as a non-employee director and vested after one year. Following this automatic equity settlement, he directly holds 119,286 common shares, with no shares sold or withheld for taxes in this Form 4.

Insider Trade Summary

2,954 shares exercised/converted

Mixed 2 txns

Insider LINK WILLIAM J PHD

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	2,954	$0.00	--
Exercise	Common Stock	2,954	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 119,286 shares (Direct, null)

Footnotes (1)

1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Each RSU represents a contingent right to receive one share of the Company's common stock. RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Key Figures

RSUs settled: 2,954 units Common shares received: 2,954 shares Holdings after transaction: 119,286 shares +2 more

5 metrics

RSUs settled 2,954 units Restricted Stock Units converted to common stock on June 12, 2026

Common shares received 2,954 shares Shares issued upon RSU settlement for non-employee director

Holdings after transaction 119,286 shares Total direct common stock ownership after RSU conversion

RSU grant date June 12, 2025 Grant date for RSUs linked to non-employee director service

RSU vesting period 1 year RSUs vest in full one year after grant, subject to service

Key Terms

Restricted Stock Units, contingent right, non-employee director, derivative security

4 terms

Restricted Stock Units financial

"The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs")."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Company's common stock."

non-employee director financial

"RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director..."

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LINK WILLIAM J PHD

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/12/2026		M(1)		2,954	A	(1)	119,286	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	06/12/2026		M			2,954	(3)	(3)	Common Stock	2,954	$0	0	D

Explanation of Responses:

1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

2. Each RSU represents a contingent right to receive one share of the Company's common stock.

3. RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Remarks:

	/s/ Jeffrey Farrow, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Tarsus Pharmaceuticals (TARS) report for William J. Link?

Tarsus Pharmaceuticals reported that director William J. Link, PhD acquired 2,954 common shares via settlement of vested RSUs. These Restricted Stock Units converted into the same number of shares upon vesting, reflecting routine equity compensation rather than an open-market stock purchase or sale.

How many Tarsus Pharmaceuticals (TARS) shares does William J. Link hold after this Form 4?

After the RSU settlement, William J. Link directly holds 119,286 shares of Tarsus Pharmaceuticals common stock. This total reflects his position following the conversion of 2,954 vested Restricted Stock Units into common shares reported in the latest Form 4 filing.

Was the Tarsus Pharmaceuticals (TARS) Form 4 an open-market buy or sale?

The Form 4 does not show an open-market buy or sale. It records an exercise/conversion of 2,954 Restricted Stock Units into common stock at $0.00 per unit, representing routine settlement of equity compensation rather than a discretionary market trade.

What are the terms of the RSUs reported in the Tarsus (TARS) Form 4?

The RSUs were granted on June 12, 2025 in connection with William J. Link’s service as a non-employee director. According to the footnotes, the units vest in full on the one-year anniversary of the grant date, subject to his continuous service on the board.

How many Restricted Stock Units were converted in the latest Tarsus Pharmaceuticals (TARS) insider filing?

The insider filing shows that 2,954 Restricted Stock Units were converted into 2,954 shares of Tarsus Pharmaceuticals common stock. Each RSU represented a contingent right to receive one share, and all units reported were fully settled in this transaction.

Did the Tarsus Pharmaceuticals (TARS) director retain any RSUs after this transaction?

No RSUs remain from this specific grant after the transaction. The derivative line in the Form 4 shows 2,954 Restricted Stock Units exercised or converted, with zero RSUs of that grant remaining outstanding, while the resulting common shares are now held directly.